Search

everythinglearnresearchcommunity

for

Search:↓

Hormone therapy is essential for transgender individuals but requires careful management due to possible metabolic effects.

The update highlights that non-classic congenital adrenal hyperplasia is common in women with excess male hormones, requires specific hormone tests for diagnosis, and has various treatment options depending on age and symptoms.

People with PCOS, especially if obese, often have NAFLD, linked to obesity, insulin resistance, and high androgen levels.

The document concludes that early recognition and treatment of PCOS in adolescents is crucial for managing symptoms and long-term health risks.

Women with PCOS who have low SHBG are more likely to have low good cholesterol and metabolic syndrome.

Testosterone therapy is generally safe for transmen, improves sexual function, and has manageable health risks with proper monitoring.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

People with lichen planus are more likely to have dyslipidemia, especially higher triglyceride levels.

Testosterone therapy seems safe and effective for transgender men with proper care, but more long-term research is needed.

Obesity worsens Polycystic Ovary Syndrome symptoms, and weight loss is a key treatment.

Hormonal treatments can improve acne, but they come with potential side effects and risks.

Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.

Older obese women with PCOS have higher cardiovascular and metabolic risks despite lower androgen levels.

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.

Young adults with hair loss face higher risk of stiff arteries.

Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.

Some men with early hair loss may have a male version of PCOS, affecting hormones and increasing health risks.

The conclusion is that managing cholesterol is important for women, especially during pregnancy, breastfeeding, and with PCOS, and involves regular screening and careful treatment choices.

The document concludes that diagnosing PCOS requires a thorough approach, considering various symptoms and risks, and calls for improved methods to identify PCOS types and prevent diabetes.

More severe hair loss links to thicker heart fat, suggesting possible heart disease risk.

Testosterone therapy for postmenopausal women appears safe and may protect against heart disease, but requires constant monitoring and more research for long-term effects.

5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.

Small hormonal imbalances can cause significant health problems, so more sensitive testing for hormone-disrupting chemicals is needed.

Anabolic steroids harm the heart, liver, hormones, muscles, and mental health.

PCOS in lean women is a serious health condition with implications beyond fertility, affecting metabolism and increasing cardiovascular disease risk.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

Minoxidil is strongly linked to heart problems, and machine learning can improve drug safety checks.

Women with PCOS have a higher risk of heart disease.

Hyperandrogenism increases heart disease risk in premenopausal women, but this risk is linked to obesity in postmenopausal women.